Literature DB >> 48384

Cytology as a guide to the presence of chlamydial inclusions in Giemsa-stained conjunctival smears in severe endemic trachoma.

C Yoneda, C R Dawson, T Daghfous, I Hoshiwara, P Jones, M Messadi, J Schachter.   

Abstract

Microscopical examination of 927 Giemsa-stained conjunctival smears from children with chronic trachoma in southern Tunisia showed 93 (10 per cent.) with typical trachoma (chlamydial) inclusions in epithelial cells. The accompanying cytological features were a useful indicator for inclusions. Inclusions were found only in slides with numerous polymorphonuclear neutrophils (PMNs) and separation of the epithelial cells. When these two features alone were present, 3 per cent. of the smears were inclusion-positive; when many lymphocytes were present also, 25 per cent. were inclusion positive; when other cytological features (plasma cells, macrophages, blastoid, and stem cells) were present as well, 70 per cent. of the smears were inclusion-positive. The occurrence of these sets of cytological features can be a useful guide for selecting smears for intensive examination for chlamydial inclusions. Immunofluorescent (FA) staining and Giemsa staining of 527 pairs of matched smears detected trachoma agent in 67 (13 per cent.); in thirty by both methods, in thirteen by Giemsa staining alone, and in 24 by FA alone. The examination of Giemsa-stained smears for chlamydial inclusions is a useful technique for the diagnosis of trachoma or inclusion conjunctivitis by laboratories that do not have the specialized facilities for the identification of these chlamydial infections by the technically more complex procedures of immunofluorescent staining or isolation in embryonated eggs or tissue cultures.

Entities:  

Mesh:

Year:  1975        PMID: 48384      PMCID: PMC1017366          DOI: 10.1136/bjo.59.3.116

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  Severe endemic trachoma in Tunisia. I. Effect of topical chemotherapy on conjunctivitis and ocular bacteria.

Authors:  D W Vastine; C R Dawson; T Daghfous; M Messadi; I Hoshiwara; C Yoneda; R Nataf
Journal:  Br J Ophthalmol       Date:  1974-10       Impact factor: 4.638

2.  Severe endemic trachoma in tunisia. II. A controlled therapy trial of topically applied chlortetracycline and erythromycin.

Authors:  C R Dawson; T Daghfous; M Messadi; I Hoshiwara; D W Vastine; C Yoneda; J Schacter
Journal:  Arch Ophthalmol       Date:  1974-09

3.  A comparison of the iodine and fluorescent antibody methods for staining trachoma inclusions in the conjunctiva.

Authors:  J Sowa; L H Collier; S Sowa
Journal:  J Hyg (Lond)       Date:  1971-12

4.  Evaluation of laboratory methods for detecting acute TRIC agent infection.

Authors:  J Schachter; C R Dawson; S Balas; P Jones
Journal:  Am J Ophthalmol       Date:  1970-09       Impact factor: 5.258

5.  Detection of Chlamydia (Bedsonia) in certain infections of man. I. Laboratory procedures: comparison of yolk sac and cell culture for detection and isolation.

Authors:  F B Gordon; I A Harper; A L Quan; J D Treharne; R S Dwyer; J A Garland
Journal:  J Infect Dis       Date:  1969-10       Impact factor: 5.226

6.  Recommended criteria for the identification of trachoma and inclusion conjunctivitis agents.

Authors:  J Schachter
Journal:  J Infect Dis       Date:  1970 Jul-Aug       Impact factor: 5.226

7.  A system of representation of cytologic features of external eye infections with special reference to trachoma.

Authors:  D Hardy; P G Surman; W H Howarth
Journal:  Am J Ophthalmol       Date:  1967-05       Impact factor: 5.258

  7 in total
  12 in total

1.  Role of neutrophils in controlling early stages of a Chlamydia trachomatis infection.

Authors:  N Barteneva; I Theodor; E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

2.  Detection of experimental Chlamydia trachomatis eye infection in conjunctival smears and in tissue culture by use of fluorescein-conjugated monoclonal antibody.

Authors:  H R Taylor; N Agarwala; S L Johnson
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

Review 3.  Spectrum of human chlamydial infections.

Authors: 
Journal:  West J Med       Date:  1981-09

4.  Intranasal inoculation of Chlamydia trachomatis mouse pneumonitis agent induces significant neutrophil infiltration which is not efficient in controlling the infection in mice.

Authors:  Hong Bai; Jie Yang; Hongyu Qiu; Shuhe Wang; Yijun Fan; Xiaobing Han; Shusheng Xie; Xi Yang
Journal:  Immunology       Date:  2005-02       Impact factor: 7.397

5.  What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting.

Authors:  Matthew J Burton; Victor H Hu; Patrick Massae; Sarah E Burr; Caroline Chevallier; Isaac A Afwamba; Paul Courtright; Helen A Weiss; David C W Mabey; Robin L Bailey
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

6.  The use of cycloheximide-treated cells for isolating trachoma agents under field conditions.

Authors:  J Schachter; C R Dawson; I Hoshiwara; T Daghfous; J Banks
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

7.  Prevalence of trachoma among children in East Jerusalem in 1980.

Authors:  S Bishara; L Yanko
Journal:  Br J Ophthalmol       Date:  1982-09       Impact factor: 4.638

8.  Toxic effect of human polymorphonuclear leukocytes on Chlamydia trachomatis.

Authors:  E C Yong; S J Klebanoff; C C Kuo
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

9.  Interaction between Chlamydia spp. and human polymorphonuclear leukocytes in vitro.

Authors:  K B Register; P A Morgan; P B Wyrick
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

10.  Trachoma therapy with topical tetracycline and oral erythromycin: a comparative trial.

Authors:  C R Dawson; T Daghfous; I Hoshiwara; K Ramdhane; M Kamoun; C Yoneda; J Schachter
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.